Compare GFS & RMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GFS | RMD |
|---|---|---|
| Founded | 2009 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 37.8B | 32.4B |
| IPO Year | 2017 | 1996 |
| Metric | GFS | RMD |
|---|---|---|
| Price | $46.36 | $235.17 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 10 |
| Target Price | $45.08 | ★ $292.56 |
| AVG Volume (30 Days) | ★ 4.2M | 1.5M |
| Earning Date | 05-05-2026 | 04-30-2026 |
| Dividend Yield | N/A | ★ 1.13% |
| EPS Growth | N/A | ★ 9.67 |
| EPS | N/A | ★ 10.43 |
| Revenue | N/A | ★ $2,957,013,000.00 |
| Revenue This Year | $7.64 | $10.60 |
| Revenue Next Year | $9.90 | $7.41 |
| P/E Ratio | $29.28 | ★ $22.60 |
| Revenue Growth | N/A | ★ 13.44 |
| 52 Week Low | $31.61 | $180.27 |
| 52 Week High | $92.55 | $284.87 |
| Indicator | GFS | RMD |
|---|---|---|
| Relative Strength Index (RSI) | 36.54 | 66.42 |
| Support Level | $40.24 | $199.75 |
| Resistance Level | $49.36 | $261.05 |
| Average True Range (ATR) | 1.98 | 6.35 |
| MACD | 0.11 | 0.76 |
| Stochastic Oscillator | 10.12 | 93.40 |
GlobalFoundries is a top-five contract semiconductor manufacturer globally. It was originally the manufacturing arm of Advanced Micro Devices before it was spun out in 2009. The foundry sells chips into a range of end markets including smartphones, PCs, Internet of Things, data centers, automotive, industrial, and so on, but primarily focuses on more mature process technologies. Until 2021, the firm was privately held by Mubadala Investment, the sovereign wealth fund of the United Arab Emirates, which remains its controlling shareholder today. GlobalFoundries merged with Chartered Semiconductor Manufacturing in 2009 and acquired IBM's chipmaking business in 2015. GF is headquartered in Malta, New York, and has about 13,000 staff.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks, and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea, combined with aging populations and increasing prevalence of obesity, is resulting in a structurally growing market. The company earns roughly two-thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan, and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor, and payer in the out-of-hospital setting.